Arcturus Reports Q1 2026 Earnings and Clinical Progress
Arcturus reported its first-quarter earnings for 2026 with cash reserves of $213.4 million as of March 31, down from December's figure but still supporting operations through mid-2028. The company noted a year-over-year revenue decline due to reduced collaboration income and lower R&D costs.
Tickers: $ARCT
Topics: biotech clinical_trials pharmaceuticals rare_diseases